Fresenius Kabi Oncology Limited (Company) has announced to the stock exchanges that its promoter Fresenius Kabi (Singapore) Private Limited. intends to undertake one or more ‘offer(s) for sale’ on the stock exchanges (OFS) for sale of up to approximately 15% of the total share capital of the Company in one or more tranches, subject to receipt of relevant regulatory approvals and the market conditions. The objective of the proposed OFS is to increase the public shareholding of the Company.

Amarchand Mangaldas’ Delhi-based partner, Akila Agrawal, is leading the transaction and is being supported by Pooja Ramchandani, Principal Associate-Designate and Mukul Sharma, Associate.